Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
RO

NASDAQ · ROIV

Roivant Sciences Ltd.

Healthcare · Biotechnology

$35.89

Down-$1.02 (-2.76%)

Updated Nov 3, 2026, 7:33 AM

SID Score

7.2/10

Composite research score

Smart Money

58/100

Neutral

Market cap
14.83B
P/E ratio
-38.83
Dividend yield
0.00%
52-week range
$19.62 – $42.50
Volume
5.72M
Avg. volume
8.16M

Price performance · ROIV

ROIV price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

ROIV closed at $35.89 after 21 trading sessions, up 0.31% for the selected period.

Last close
$35.89
Period change
+0.31%
Period low
$33.35
Period high
$37.52
Daily close
View OHLC price history
ROIV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$36.95$37.29$35.81$35.895.72M
Oct 30, 2026$37.11$37.9366$36.78$36.914.57M
Oct 29, 2026$37.44$37.97$37.29$37.523.73M
Oct 28, 2026$36.43$37.13$36.13$37.115.77M
Oct 27, 2026$35.94$36.83$35.80$36.546.57M
Oct 26, 2026$36.66$36.91$35.66$36.059.87M
Oct 23, 2026$37.18$37.42$36.36$36.498.23M
Oct 22, 2026$36.68$38.49$36.68$37.4513.45M
Oct 21, 2026$38.15$38.49$35.99$36.8016.84M
Oct 20, 2026$35.00$35.515$34.38$34.923.67M
Oct 19, 2026$33.78$35.14$33.60$34.706.33M
Oct 16, 2026$34.12$34.12$33.23$33.534.92M
Oct 15, 2026$33.82$34.355$33.70$34.044.57M
Oct 14, 2026$33.14$34.09$33.00$33.624.29M
Oct 13, 2026$34.44$34.915$33.26$33.356.32M
Oct 12, 2026$34.92$35.41$34.55$34.594.73M
Oct 9, 2026$34.24$35.59$34.15$35.445.53M
Oct 8, 2026$34.275$34.56$33.32$34.216.4M
Oct 7, 2026$35.22$35.485$34.63$34.755.74M
Oct 6, 2026$35.86$36.34$34.75$35.535.74M
Oct 5, 2026$35.98$36.325$35.245$35.786.2M

Latest ROIV news

The latest Smart Investors Daily articles mentioning ROIV.

Stock researchCompany · Overview

ROIV research

Overview

Company profile and research snapshot.

Company profile

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$23.50
Implied upside
—
Analysts
—
ROIV recent ratings
DateFirmRatingTarget
Oct 28, 2026CitigroupBuy—
Oct 12, 2026Wolfe ResearchPeer Perform—
Sep 17, 2026StifelBuy—
Sep 9, 2026TD CowenBuy—
Sep 9, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Today Roivant Social Ventures (RSV) announced it is joining efforts with No Patient Left Behind (NPLB) to improve drug affordability and access while supporting ongoing medical innovation, through a six-figure legacy donation. RSV is a 501(c)3 public charity and social impact organization that partners with innovative companies, institutes, and organizations to promote systemic, sustained improvements to the way health care is accessed and delivered. T

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By